S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Retirement Plans in 2023: Choosing the Right Account
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Retirement Plans in 2023: Choosing the Right Account
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Retirement Plans in 2023: Choosing the Right Account
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Retirement Plans in 2023: Choosing the Right Account
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
NASDAQ:BIOL

BIOLASE - BIOL Stock Forecast, Price & News

$0.56
+0.02 (+4.05%)
(As of 02/2/2023 09:11 AM ET)
Add
Compare
Today's Range
$0.56
▼
$0.56
50-Day Range
$0.38
▼
$1.02
52-Week Range
$0.37
▼
$10.70
Volume
11,052 shs
Average Volume
1.08 million shs
Market Capitalization
$4.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

BIOLASE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,658.9% Upside
$9.50 Price Target
Short Interest
Healthy
12.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of BIOLASE in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2,653 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

See Top Rated MarketRank™ Stocks Here

BIOL stock logo

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

January 30, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)
January 25, 2023 | finance.yahoo.com
BIOLASE REJECTS SONENDO'S "PATENTLY ABSURD" CLAIMS
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 23, 2023 | marketwatch.com
Medical Lasers Market (New Research Insights) Dominated Regions 2023: Upcoming Demand, Global Size and Share Forecast to 2027
January 23, 2023 | americanbankingnews.com
BIOLASE's (BIOL) "Buy" Rating Reiterated at Lake Street Capital
January 18, 2023 | finance.yahoo.com
BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023
January 12, 2023 | finance.yahoo.com
BIOLASE RECEIVES TOP WORKPLACES 2022 AWARD
January 10, 2023 | finance.yahoo.com
BIOLASE INC. ANNOUNCES PRICING OF APPROXIMATELY $9.75 MILLION UNDERWRITTEN PUBLIC OFFERING
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 29, 2022 | marketwatch.com
The Dental Diode Lasers market research report's industry experts have examined the profitability and growth possibilities.
December 28, 2022 | marketwatch.com
With 2.7% CAGR, Dental Equipment Market 2023 To Garner Overwhelming Hike In Revenues by 2028 | 106 Pages Report
December 18, 2022 | marketwatch.com
Dental Tourism Market is booming in near Future 2023-2028
November 14, 2022 | finance.yahoo.com
BIOLASE to Participate in the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 in New York
November 10, 2022 | finance.yahoo.com
BIOLASE DELIVERS 26% REVENUE GROWTH YEAR OVER YEAR IN THIRD QUARTER AND RAISES 2022 FULL YEAR REVENUE GUIDANCE
October 27, 2022 | finance.yahoo.com
BIOLASE, Inc to Report Third Quarter 2022 Results on November 10, 2022
October 18, 2022 | benzinga.com
Outlook on the Cosmetic Dentistry Global Market to 2030 - Featuring 3M, Sirona Dental Systems, A-Dec and - Benzinga
October 13, 2022 | finance.yahoo.com
BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER
October 6, 2022 | globenewswire.com
Rising Concerns about the Dental Hygiene Due to the Changing Lifestyle is Uplifting the Periodontal Market: Future Market Insights, Inc. - GlobeNewswire
October 6, 2022 | benzinga.com
Global Cosmetic Dentistry Market Report (2022 to 2030) - Increasing Consumer Awareness and Rising Focus o - Benzinga
October 5, 2022 | finance.yahoo.com
BIOLASE LAUNCHES RESEARCH GRANT PORTAL TO ACCELERATE CLINICAL STUDIES ON INNOVATIVE DENTAL LASER TECHNOLOGY
October 1, 2022 | money.usnews.com
Biolase Inc
September 30, 2022 | globenewswire.com
Dental Laser Market to Hit Sales of $337.08 Million By 2028 | US is the Largest Export of Dental Lasers | SkyQuest Technology - GlobeNewswire
September 22, 2022 | finance.yahoo.com
BIOLASE DOCUSERIES, "TALK DENTAL TO ME" TO BE PRODUCED BY PROVIDENCE FILM GROUP
September 7, 2022 | msn.com
Biolase Earnings Perspective: Return On Capital Employed
September 6, 2022 | benzinga.com
(BIOL) – Biolase Earnings Perspective: Return On Capital Employed - Benzinga
August 31, 2022 | finance.yahoo.com
Worldwide Dental Equipment Industry to 2027 - Rising Geriatric Population is Driving Growth - Yahoo Finance
August 31, 2022 | finance.yahoo.com
BIOLASE ANNOUNCES DEVELOPMENT OF STRATEGIC PLAN TO PARTNER WITH POSTGRADUATE DENTAL SPECIALTY PROGRAMS ACROSS THE U.S.
See More Headlines
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Company Calendar

Last Earnings
11/10/2022
Today
2/02/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
CUSIP
N/A
CIK
811240
Web
www.biolase.com
Phone
(949) 361-1200
Fax
949-273-6677
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,590.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,160,000.00
Net Margins
-51.38%
Pretax Margin
-51.17%
Return on Equity
-118.42%
Return on Assets
-48.29%

Debt

Debt-to-Equity Ratio
0.92
Current Ratio
2.46
Quick Ratio
1.27

Sales & Book Value

Annual Sales
$39.19 million
Price / Sales
0.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.11 per share
Price / Book
0.14

Miscellaneous

Outstanding Shares
7,720,000
Free Float
7,559,000
Market Cap
$4.34 million
Optionable
Not Optionable
Beta
1.38

Key Executives

  • John R. Beaver
    President, Chief Executive Officer & Director
  • Steven Sandor
    Chief Operating Officer
  • Jennifer Brighton
    Chief Financial Officer
  • Russell Morrow
    Chief Dental Officer
  • William E. Brown
    Vice President-Innovation & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.

What is BIOLASE's stock price forecast for 2023?

3 analysts have issued 12-month price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $5.00 to $14.00. On average, they expect the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 1,658.9% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2023?

BIOLASE's stock was trading at $0.65 at the beginning of the year. Since then, BIOL stock has decreased by 16.9% and is now trading at $0.5401.
View the best growth stocks for 2023 here.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our BIOL earnings forecast.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) released its earnings results on Thursday, November, 10th. The medical technology company reported ($1.10) earnings per share for the quarter. The medical technology company had revenue of $12.01 million for the quarter. BIOLASE had a negative net margin of 51.38% and a negative trailing twelve-month return on equity of 118.42%.

When did BIOLASE's stock split?

BIOLASE shares reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its fourth quarter 2022 earnings guidance on Sunday, January, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.00 million-$14.40 million, compared to the consensus revenue estimate of $13.18 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a number of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (0.60%). Insiders that own company stock include Jack W Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.54.

How much money does BIOLASE make?

BIOLASE (NASDAQ:BIOL) has a market capitalization of $4.17 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How many employees does BIOLASE have?

The company employs 158 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 2/2/2023 by MarketBeat.com Staff